Maternal Serum Adropin in Placenta Accreta Spectrum

Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.

Methods:

This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Inclusion Criteria:

• Pregnant women aged 18-45 years in the reproductive period
• Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS

Exclusion Criteria:

• Uterine anomalies,
• Chronic systemic diseases,
• Multiple pregnancies,
• Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.